The stock of OHR Pharmaceutical Inc (NASDAQ:OHRP) is a huge mover today! The stock increased 15.38% or $0.44 on October 17, hitting $3.3. About 374,355 shares traded hands or 555.42% up from the average. OHR Pharmaceutical Inc (NASDAQ:OHRP) has declined 13.86% since March 14, 2016 and is downtrending. It has underperformed by 19.47% the S&P500.
The move comes after 9 months positive chart setup for the $107.07 million company. It was reported on Oct, 17 by Barchart.com. We have $4.36 PT which if reached, will make NASDAQ:OHRP worth $34.26 million more.
Analysts await OHR Pharmaceutical Inc (NASDAQ:OHRP) to report earnings on December, 8. They expect $-0.26 earnings per share, down 100.00% or $0.13 from last year’s $-0.13 per share. After $-0.24 actual earnings per share reported by OHR Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.33% negative EPS growth.
According to Zacks Investment Research, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 0.88 in 2016 Q2. Its down 0.12, from 1 in 2016Q1. The ratio fall, as 5 funds sold all OHR Pharmaceutical Inc shares owned while 12 reduced positions. 7 funds bought stakes while 8 increased positions. They now own 3.46 million shares or 15.92% less from 4.11 million shares in 2016Q1.
Garrison Bradford Assocs holds 90,200 shares or 0.24% of its portfolio. The Pennsylvania-based Bryn Mawr Trust Co has invested 0% in OHR Pharmaceutical Inc (NASDAQ:OHRP). Susquehanna Int Llp has invested 0% of its portfolio in OHR Pharmaceutical Inc (NASDAQ:OHRP). Finemark Retail Bank & last reported 22,589 shares in the company. Moreover, Opaleye Mgmt has 1.36% invested in OHR Pharmaceutical Inc (NASDAQ:OHRP) for 146,700 shares. Creative Planning owns 11,500 shares or 0% of their US portfolio. Grp Inc One Trading Ltd Partnership last reported 18,632 shares in the company. Morgan Stanley holds 0% or 5,200 shares in its portfolio. The New York-based Art Advsr Lc has invested 0.01% in OHR Pharmaceutical Inc (NASDAQ:OHRP). Westwood Mgmt Il holds 0.01% of its portfolio in OHR Pharmaceutical Inc (NASDAQ:OHRP) for 20,000 shares. Pnc Financial Svcs Grp Incorporated Incorporated last reported 51,521 shares in the company. Price T Rowe Assocs Incorporated Md has invested 0% of its portfolio in OHR Pharmaceutical Inc (NASDAQ:OHRP). Wells Fargo & Mn last reported 167 shares in the company. Dimensional Fund Advsr Limited Partnership, a Texas-based fund reported 27,517 shares. Financial Bank Of New York Mellon accumulated 60,069 shares or 0% of the stock.
Insider Transactions: Since May 23, 2016, the stock had 3 buys, and 0 selling transactions for $107,750 net activity. Shares for $11,447 were bought by Slakter Jason Scott. On Monday, May 23 Backenroth Samuel bought $7,926 worth of the stock or 2,500 shares.
Another recent and important OHR Pharmaceutical Inc (NASDAQ:OHRP) news was published by Marketwatch.com which published an article titled: “Ohr Pharmaceutical downgraded to hold from buy at Brean Capital” on June 28, 2011.
OHRP Company Profile
Ohr Pharmaceutical, Inc., incorporated on May 8, 2014, is a pharmaceutical company. The Firm is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program, OHR-102 eye drops, is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Firm focuses on OHR-102 eye drops, which is given in combination with Lucentis injections, for the treatment of retinal diseases, including wet-age-related macular degeneration (AMD), retinal vein occlusion and proliferative diabetic retinopathy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.